Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
Not yet accepting
ELRiSE MDS
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (ELRiSE MDS)
- Activin Receptor IIA Inhibitor
- Randomization
- Phase 3
Accepting patients
RALLY-MF
RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
- Monoclonal Antibody
- Hemojuvelin (HJV)
- Randomization
- Monotherapy
- Phase 1/2
- Has results
Accepting patients
IRAK
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
- IRAK 4 Inhibitor
- IRAK 1 Inhibitor
- Phase 1/2
- Has results
Accepting patients
BH-30236
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- CLK Inhibitor
- Phase 1
Accepting patients
AZTOUND
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- DNMT1 Inhibitor
- Phase 2/3
- Has results
Accepting patients
Impact of Non-Profit on Patient Outcomes & Care
The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial
- Randomization
- Observational Trial
Accepting patients
Safety Study of Cord Blood Units
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Tyrosine Kinase (TK) Inhibitor
- FLT3 Inhibitor
- Phase 1
Accepting patients
NEROFE
An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- Phase 1
Not yet accepting
AZD2962
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
- IRAK 4 Inhibitor
- Phase 1